Astellas v. Sandoz: Federal Circuit Vacates & Remands Modified-Release Drug Patent Ruling
Astellas Pharma and its affiliates brought an infringement action against Sandoz over US10842780B2, covering a modified-release pharmaceutical composition. After 453 days, the Federal Circuit vacated the lower decision and remanded, sending the dispute back for further proceedings rather than ending it.
Federal Circuit nullifies lower ruling in Astellas–Sandoz modified-release dispute
Astellas Pharma, Inc., Astellas Pharma Global Development, Inc., and Astellas Ireland Co., Ltd. (collectively Astellas) filed this infringement appeal before the Court of Appeals for the Federal Circuit on 23 June 2023, asserting rights in US10842780B2. The patent, filed under application number US15/432854, covers a pharmaceutical composition for modified release — a formulation technology central to controlled-dosing drug products and a competitive battleground in generic pharmaceutical development.
The Federal Circuit issued its disposition on 18 September 2024, ordering the lower court decision vacated and the matter remanded. Vacatur at the appellate level means the prior ruling carries no precedential or binding weight; the case returns to the originating tribunal for reconsideration consistent with the Federal Circuit’s guidance. Neither party obtained a final merits victory at this stage, and the underlying infringement question over US10842780B2 remains unresolved.
The 453-day appellate timeline suggests the Federal Circuit engaged substantively with the issues rather than disposing of the appeal on a purely procedural basis. The precise grounds for vacatur are not detailed in the publicly available docket summary, but vacatur-and-remand outcomes in pharmaceutical patent appeals typically signal that the lower tribunal applied an incorrect legal standard, made a clearly erroneous factual finding, or failed to adequately address a claim construction or obviousness issue. The ultimate commercial outcome for both parties depends on the remand proceedings.
Filing to Vacated and Remanded in 453 days
453 days — above median for Federal Circuit pharmaceutical patent appeals
Federal Circuit vacates: what the remand means for both parties
Vacatur nullifies the lower decision entirely
When the Federal Circuit vacates a district court or PTAB decision, the ruling below is legally nullified — it cannot be cited as precedent or enforced. The case is remanded, meaning the originating tribunal must reconsider the matter, typically under legal standards or factual frameworks clarified by the appellate court. Vacatur does not mean either party wins on the merits; it resets the dispute at the lower level.
Appellate vacaturAstellas gets a second chance — but no guaranteed win
For Astellas, vacatur is a meaningful procedural victory if the lower decision had gone against them: the unfavourable ruling is erased. However, the remand means Astellas must relitigate the relevant issues before the lower tribunal. US10842780B2 remains in force during remand, and Astellas retains the ability to press its infringement claims, but final vindication depends on the outcome of the proceedings below.
Patent survives; remand pendingSandoz faces renewed proceedings without a clean win
Sandoz did not obtain a final determination of non-infringement or invalidity at this stage. If the lower court had ruled in Sandoz’s favour, that protective decision has now been erased. Sandoz must re-engage with the proceedings on remand, bearing the costs and uncertainty of further litigation. Any commercial freedom-to-operate premised on the vacated decision should be treated as legally unreliable until the remand resolves.
No final clearance obtainedModified-release market certainty delayed for generic entrants
Vacatur-and-remand outcomes extend commercial uncertainty for both branded and generic manufacturers. Generic market entry that might have been permitted — or blocked — under the vacated decision remains in legal limbo. Companies developing modified-release formulations in Astellas’s product space should monitor the remand closely, as the eventual lower-court decision will reset the risk calculus for Freedom to Operate and ANDA filing strategies in this segment.
Market entry timeline uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Astellas Pharma, Inc. | Company | Pharmaceutical group (Astellas) — holder of US10842780B2 covering modified-release compositionsSearch in Eureka ↗ |
| Co-Plaintiff | Astellas Pharma Global Development, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Astellas Ireland Co., Ltd. | Company | Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Sandoz, Inc. — generic pharmaceutical manufacturer contesting patent infringementSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Dominick Gattuso | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Heyman Enerio Gattuso & Hirzel, LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘VACATED AND REMANDED’ — carries significant weight in pharmaceutical patent litigation. Vacatur nullifies the lower tribunal’s decision in its entirety, stripping it of any legal effect. The remand instruction signals that the Federal Circuit identified a reversible error requiring fresh consideration rather than simply entering judgment for either party. The appellate standard for vacatur typically requires a finding of legal error or clearly erroneous factual determination. The public record does not specify the precise grounds, but the outcome suggests the lower court’s analysis of US10842780B2 — whether on infringement, validity, or claim construction — did not survive Federal Circuit scrutiny.
US10842780B2 — Modified-Release Pharmaceutical Composition
US10842780B2 (application US15/432854) is held by Astellas and covers a pharmaceutical composition designed for modified release — a formulation approach that controls the rate, timing, or location of active pharmaceutical ingredient delivery in the body. Modified-release technologies are critical to dosing consistency, patient compliance, and therapeutic efficacy, and are widely deployed across oral solid dosage forms in branded and generic drug markets.
For Astellas, US10842780B2 represents a commercially significant IP asset in a segment where generic entry is aggressively contested. Modified-release formulation patents are frequent targets in ANDA litigation under the Hatch-Waxman framework because generic manufacturers must certify invalidity or non-infringement to seek approval. A successful defence of this patent on remand could extend market exclusivity meaningfully; loss could accelerate generic competition. Competitors and ANDA filers active in the modified-release oral dosage space should treat this patent as a live, unresolved risk.
Should you run an FTO analysis against US10842780B2?
Any company developing, manufacturing, or commercialising modified-release pharmaceutical compositions — particularly oral solid dosage forms — should assess exposure to US10842780B2 before advancing products through IND, ANDA, or NDA filings. The Federal Circuit’s vacatur means the patent’s enforceability and precise claim scope remain actively contested. Proceeding without an FTO assessment in this product category carries material legal and commercial risk.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map claims of US10842780B2 against their own formulation approaches, identify relevant prior art, and surface related Astellas portfolio filings that may extend coverage beyond this single patent. With the remand proceedings ongoing, regular monitoring of new claim constructions and related prosecution history is essential for any team active in modified-release drug development.
Run a freedom-to-operate analysis on US10842780B2 to assess your product’s exposure
Run FTO in Eureka →Similar modified-release pharmaceutical patent cases at the Federal Circuit
Federal Circuit appeals involving modified-release pharmaceutical composition patents and Hatch-Waxman ANDA disputes — cases with comparable claim construction and vacatur dynamics.
What this case signals for the modified-release pharmaceutical IP landscape
Federal Circuit vacatur keeps high-value modified-release formulation patents in active dispute — and reshapes generic launch risk for the sector.
Vacated decisions offer no commercial shelter for generic manufacturers
Any generic manufacturer that factored the now-vacated lower ruling into its launch calculus for competing modified-release products should reassess. Vacatur erases the legal basis of that ruling. Until the remand produces a new final decision, Freedom to Operate for products potentially covered by US10842780B2 cannot be assumed.
Remand signals a substantive Federal Circuit concern — watch the reasoning
The Federal Circuit does not vacate lightly. A vacatur-and-remand in a pharmaceutical infringement case typically indicates a material error in claim construction, obviousness analysis, or evidentiary standard. The remand opinion’s reasoning — once published — will likely set precedent for how similar modified-release composition claims are adjudicated going forward.
Astellas v Sandoz — key questions answered
In case 23-2063, the Federal Circuit vacated the lower tribunal’s decision, nullifying it entirely, and remanded the matter for reconsideration. Neither Astellas nor Sandoz obtained a final merits determination. The infringement dispute over US10842780B2 returns to the originating court for further proceedings under guidance from the Federal Circuit.
US10842780B2 (application US15/432854), held by Astellas, covers a pharmaceutical composition for modified release. Modified-release formulations control drug delivery rate and timing, making them central to branded drug differentiation and a frequent target in Hatch-Waxman ANDA litigation. The patent’s commercial significance lies in its potential to restrict generic market entry into Astellas’s modified-release product segment.
No. Vacatur removes the legal effect of the lower court decision but does not grant Sandoz a freedom-to-operate clearance. Until the remand produces a new final decision — and any further appeals conclude — the infringement and validity questions surrounding US10842780B2 remain unresolved. Generic launch based on the vacated ruling would carry significant legal risk.
Federal Circuit vacatur-and-remand outcomes typically indicate the lower tribunal applied an incorrect legal standard, erred in claim construction, or made a clearly erroneous factual finding. In pharmaceutical patent cases, common grounds include errors in obviousness analysis, claim scope determination, or the application of Hatch-Waxman-specific procedural rules. The public record for 23-2063 does not specify the precise grounds.
Astellas was represented by Daniel M. Silver of McCarter & English LLP. Sandoz was represented by Dominick Gattuso of Heyman Enerio Gattuso & Hirzel, LLP. The case was filed at the Court of Appeals for the Federal Circuit on 23 June 2023 and closed on 18 September 2024.
PatSnap Eureka searches patents and litigation data to answer instantly.